Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions
- 26 April 2019
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics
- Vol. 37 (9) , 1093-1127
Abstract
Previous systematic reviews concluded that pneumococcal vaccination in the elderly was cost effective. However, recently published economic evaluations state that it may not be cost effective when children are vaccinated with higher-valent pneumococcal conjugate vaccines. The literature suggests that the outcomes of vaccination in the elderly are strongly influenced by the vaccine effectiveness (VE) against the vaccine-type pneumococcal diseases (PD) and the impact of childhood vaccination on the vaccine-type PD incidence in the elderly, but the extent remains unclear.Keywords
Funding Information
- Gottfried Wilhelm Leibniz Universität Hannover
This publication has 72 references indexed in Scilit:
- Systematic review of economic evaluations of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in individuals 60 years of age or olderVaccine, 2018
- Evolution over time in the cost-effectiveness of pneumococcal conjugate vaccine (PCV13) in older Australians due to herd protection from infant vaccinationVaccine, 2018
- Economic evaluation of pneumococcal vaccines for adults aged over 50 years in BelgiumHuman Vaccines & Immunotherapeutics, 2018
- The role of timeliness in the cost-effectiveness of older adult vaccination: A case study of pneumococcal conjugate vaccine in AustraliaVaccine, 2018
- Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysisThe Lancet Global Health, 2017
- Evaluating the costs and benefits of pneumococcal vaccination in adultsExpert Review of Vaccines, 2016
- Pneumococcal serotype evolution in Western EuropeBMC Infectious Diseases, 2015
- A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderlyHuman Vaccines & Immunotherapeutics, 2015
- Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in AdultsNew England Journal of Medicine, 2015
- Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: A systematic review of conclusions and assumptionsVaccine, 2009